Recruiting

Study Comparing FDG-PET/CT and CT for Monitoring Treatment Response in Patients with Metastatic Breast Cancer Using Fludeoxyglucose (18F)

Fast replyRegistered drugNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying metastatic breast cancer, which is a type of breast cancer that has spread to other parts of the body. The study will compare two different methods of monitoring how well the cancer is responding to treatment. One method uses a special type of scan called FDG-PET/CT, which involves a small amount of radioactive sugar to help show cancer activity in the body. The other method uses a more traditional scan known as computed tomography (CT), which takes detailed pictures of the inside of the body.

The purpose of the study is to find out if using FDG-PET/CT is better than using CT for checking how the cancer is responding to treatment, with the hope of improving overall survival for patients. Participants in the study will be randomly assigned to have their cancer monitored with either FDG-PET/CT or CT. The study will follow participants over time to see which method provides better information about the cancer's response to treatment.

Throughout the study, researchers will also look at other important factors, such as the quality of life of the participants, the time they spend on cancer treatment, and the cost-effectiveness of the monitoring methods. The study aims to provide valuable insights that could help improve the care and outcomes for people with metastatic breast cancer.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Joining the study
Upon joining the study, you will be required to sign an informed consent form. This document confirms your understanding of the study and your willingness to participate.
You must meet certain criteria, such as being 18 years or older, having a diagnosis of metastatic breast cancer, and being eligible for first-line systemic treatment and continuous monitoring by scans.
Step 2
Initial assessment
An initial assessment will be conducted to gather baseline information about your health and the status of your cancer. This may include physical examinations, blood tests, and imaging scans.
Step 3
Randomization
You will be randomly assigned to one of two groups: one group will undergo monitoring with FDG-PET/CT scans, and the other group will undergo monitoring with conventional CT scans.
Step 4
Treatment and monitoring
You will receive the standard treatment for metastatic breast cancer, which may include medications and therapies as determined by your healthcare provider.
Regular monitoring will be conducted using the assigned imaging method to evaluate your response to treatment. The frequency and duration of these scans will be determined by the study protocol.
Step 5
Follow-up assessments
Throughout the study, follow-up assessments will be conducted to monitor your overall health, quality of life, and any side effects from the treatment.
These assessments may include questionnaires, interviews, and additional medical tests.
Step 6
Completion of the study
The study is expected to continue until December 31, 2029. Upon completion, a final assessment will be conducted to gather data on your overall survival and quality of life.
Results from the study will contribute to understanding the effectiveness of FDG-PET/CT versus conventional CT in monitoring metastatic breast cancer.

Who can join the trial?

7 criteria

Women and men aged 18 years or older.
Diagnosis of distant relapsed metastatic breast cancer (MBC) confirmed by a biopsy, which is a small sample of tissue taken from the body to check for cancer cells.
For patients with de novo breast cancer (newly diagnosed), a biopsy of the primary tumor and imaging tests showing distant metastasis are required.
Eligible for first-line systemic treatment, which is the initial treatment given for cancer that affects the whole body.
Eligible for continuous treatment monitoring by scans, meaning regular imaging tests to check how the treatment is working.
Must have signed informed consent, which means agreeing to participate in the study after being fully informed about it.
Must be able to read and understand the language required for the study in their country: Danish in Denmark, Italian or English in Italy, and German or English in Germany.

Who cannot join the trial?

3 criteria

Patients who do not have metastatic breast cancer cannot participate. Metastatic means the cancer has spread to other parts of the body.
Patients who are not within the specified age range cannot participate. The age range includes adults and older adults.
Patients who are part of a vulnerable population cannot participate. Vulnerable populations include groups that may need special protection or care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Verified
Aalborg University Hospital
Aalborg, Denmark
Verified
Aarhus University Hospital
Aarhus, Denmark
Responsive
Roskilde University
Roskilde, Denmark

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

FDG-PET/CT is a type of imaging test that helps doctors see how your body is functioning. It uses a small amount of radioactive sugar to look for cancer cells in your body. This test is used in the trial to monitor how well the treatment is working for patients with metastatic breast cancer. It helps doctors see if the cancer is shrinking, staying the same, or growing.

CT, or computed tomography, is another type of imaging test that creates detailed pictures of the inside of your body. In this trial, CT scans are used to monitor the response of metastatic breast cancer to treatment. It helps doctors assess changes in the size of the cancer and determine how well the treatment is working.

Fludeoxyglucose (18F)

What is already known about the treatment

FDG-PET/CT – FDG-PET/CT is a diagnostic imaging method used to monitor the response of metastatic breast cancer to treatment. It involves the administration of a radioactive sugar substance, which is injected into the bloodstream and then imaged using a PET/CT scanner. This method is currently being evaluated in clinical trials to determine if it provides better monitoring of cancer treatment response compared to conventional CT scans. The main therapeutic indication for FDG-PET/CT in this trial is metastatic breast cancer, and it works by highlighting areas of high metabolic activity, which are often indicative of cancerous cells. FDG-PET/CT is classified as a diagnostic imaging tool rather than a pharmacological treatment.

Investigated diseases

Metastatic breast cancer – Metastatic breast cancer is a stage of breast cancer where the cancer cells have spread beyond the breast to other parts of the body, such as the bones, liver, lungs, or brain. This spread occurs when cancer cells break away from the original tumor and travel through the bloodstream or lymphatic system. The disease progresses as these cancer cells establish new tumors in other organs, disrupting their normal function. Symptoms can vary depending on the organs affected but may include bone pain, difficulty breathing, or neurological symptoms. The progression of metastatic breast cancer can be unpredictable, with periods of stability and periods of rapid growth. The disease is considered chronic, requiring ongoing management to control symptoms and slow progression.